Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence

References

• Centers for Disease Control and Prevention. Data and statistics on Down syndrome. Available from: https://www.cdc.gov/ncbddd/birthdefects/downsyndrome/data.html. Accessed September 30, 2021.
   Google Scholar
• Antonarakis SE, Skotko BG, Rafii MS, et al. Down syndrome. Nat Rev Dis Primers. 2020;6(1):9. doi:10.1038/s41572-019-0143-7
   PubMed Web of Science ®Google Scholar
• Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004;5:725–738. doi:10.1038/nrg1448
   PubMed Web of Science ®Google Scholar
• Letourneau A, Santoni F, Bonilla X, et al. Domains of genome-wide gene expression dysregulation in Down’s syndrome. Nature. 2014;508:345–350. doi:10.1038/nature13200
   PubMed Web of Science ®Google Scholar
• Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164:9–16. doi:10.1111/j.1365-2249.2011.04335.x
   PubMed Web of Science ®Google Scholar
• Kusters MAA, Verstegen RHJ, Gemen EFA, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. 2009;156:189–193. doi:10.1111/j.1365-2249.2009.03890.x
   PubMed Web of Science ®Google Scholar
• Levo Y, Green P. Down’s syndrome and autoimmunity. Am J Med Sci. 1977;273:95–100. doi:10.1097/00000441-197701000-00010
   PubMed Web of Science ®Google Scholar
• Lejeune J, Gautier M, Turpin R. A study of somatic chromosomes in nine infants with mongolism. CR Acad Sci. 1959;248:1721–1722.
   PubMed Web of Science ®Google Scholar
• Gardiner K, Costa ACS. The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet. 2006;142:196–205. doi:10.1002/ajmg.c.30098
   Google Scholar
• Lana-Elola E, Watson-Scales SD, Fisher EMC, Tybulewicz VLJ. Down syndrome: searching for the genetic culprits. Dis Model Mech. 2011;4:586–595. doi:10.1242/dmm.008078
   PubMed Web of Science ®Google Scholar
• Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66(5):924–931. doi:10.7326/0003-4819-66-5-924
   PubMed Web of Science ®Google Scholar
• Tan YH, Schneider EL, Tischfield J, Epstein CJ, Ruddle FH. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science. 1974;186(4158):61–63. doi:10.1126/science.186.4158.61
   PubMed Web of Science ®Google Scholar
• Cupples CG, Tan YH. Effect of human interferon preparations on lymphoblastogenesis in Down’s syndrome. Nature. 1977;267:165–167. doi:10.1038/267165a0
   PubMed Web of Science ®Google Scholar
• Sullivan KD, Lewis HC, Hill AA, et al. Trisomy 21 consistently activates the interferon response. eLife. 2016;5:e16220. doi:10.7554/eLife.16220
   PubMed Web of Science ®Google Scholar
• Araya P, Waugh KA, Sullivan KD, et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc Natl Acad Sci. 2019;116:24231–24241. doi:10.1073/pnas.1908129116
   PubMed Web of Science ®Google Scholar
• Waugh KA, Araya P, Pandey A, et al. Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome. Cell Rep. 2019;29(7):1893–1908 e4. doi:10.1016/j.celrep.2019.10.038
   PubMed Web of Science ®Google Scholar
• Kong XF, Worley L, Rinchai D, et al. Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. J Clin Immunol. 2020;40(6):807–819. doi:10.1007/s10875-020-00803-9
   PubMed Web of Science ®Google Scholar
• Espinosa JM. Down syndrome and COVID-19: a perfect storm? Cell Rep Med. 2020;1(2):100019. doi:10.1016/j.xcrm.2020.100019
   PubMedGoogle Scholar
• Villani ER, Carfì A, Di Paola A, et al. Clinical characteristics of individuals with Down syndrome deceased with CoVID-19 in Italy-A case series. Am J Med Genet A. 2020;182(12):2964–2970. doi:10.1002/ajmg.a.61867
   PubMed Web of Science ®Google Scholar
• Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021;174(4):572–576. doi:10.7326/m20-4986
   PubMed Web of Science ®Google Scholar
• Emami A, Javanmardi F, Akbari A, Asadi-Pooya AA. COVID-19 in patients with Down syndrome. Neurol Sci. 2021;42(5):1649–1652. doi:10.1007/s10072-021-05091-8
   PubMed Web of Science ®Google Scholar
• Hüls A, Costa ACS, Dierssen M, et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine. 2021;33:100769. doi:10.1016/j.eclinm.2021.100769
   PubMedGoogle Scholar
• Malle L, Gao C, Hur C, et al. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genet Med. 2021;23(3):576–580. doi:10.1038/s41436-020-01004-w
   PubMed Web of Science ®Google Scholar
• Storm W. Prevalence and diagnostic significance of gliadin antibodies in children with Down syndrome. Eur J Pediatr. 1990;149(12):833–834. doi:10.1007/bf02072069
   PubMed Web of Science ®Google Scholar
• Castro M, Crinò A, Papadatou B, et al. Down’s syndrome and celiac disease: the prevalence of high IgA-antigliadin antibodies and HLA-DR and DQ antigens in trisomy 21. J Pediatr Gastroenterol Nutr. 1993;16(3):265–268. doi:10.1097/00005176-199304000-00007
   PubMed Web of Science ®Google Scholar
• Gale L, Wimalaratna H, Brotodiharjo A, Duggan JM. Down’s syndrome is strongly associated with coeliac disease. Gut. 1997;40(4):492–496. doi:10.1136/gut.40.4.492
   PubMed Web of Science ®Google Scholar
• Carlsson A, Axelsson I, Borulf S, et al. Prevalence of IgA-antigliadin antibodies and IgA-antiendomysium antibodies related to celiac disease in children with Down syndrome. Pediatrics. 1998;101(2):272–275. doi:10.1542/peds.101.2.272
   PubMed Web of Science ®Google Scholar
• Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down’s syndrome: a record linkage study. Arch Dis Child. 2004;89(11):1014–1017. doi:10.1136/adc.2003.046219
   PubMed Web of Science ®Google Scholar
• Hansson T, Dahlbom I, Rogberg S, et al. Antitissue transglutaminase and antithyroid autoantibodies in children with Down syndrome and celiac disease. J Pediatr Gastroenterol Nutr. 2005;40(2):170–4;discussion 125–7. doi:10.1097/00005176-200502000-00016
   Web of Science ®Google Scholar
• AlRuwaily F, Kattan HA, AlMehaidib AM, AlDekhail W. Prevalence of celiac disease in Saudi children with Down syndrome: a retrospective study. Int J Pediatr Adolesc Med. 2017;4(2):51–53. doi:10.1016/j.ijpam.2016.12.002
   PubMedGoogle Scholar
• Carnicer J, Farré C, Varea V, Vilar P, Moreno J, Artigas J. Prevalence of coeliac disease in Down’s syndrome. Eur J Gastroenterol Hepatol. 2001;13(3):263–267. doi:10.1097/00042737-200103000-00008
   PubMed Web of Science ®Google Scholar
• George EK, Mearin ML, Bouquet J, et al. High frequency of celiac disease in Down syndrome. J Pediatr. 1996;128(4):555–557. doi:10.1016/s0022-3476(96)70369-4
   PubMed Web of Science ®Google Scholar
• Zachor DA, Mroczek-Musulman E, Brown P. Prevalence of celiac disease in Down syndrome in the United States. J Pediatr Gastroenterol Nutr. 2000;31(3):275–279. doi:10.1097/00005176-200009000-00014
   PubMed Web of Science ®Google Scholar
• Abdulrazzaq Y, El-Azzabi TI, Al Hamad SM, Attia S, Deeb A, Aburawi EH. Occurrence of hypothyroidism, diabetes mellitus, and celiac disease in Emirati children with Down’s syndrome. Oman Med J. 2018;33(5):387–392. doi:10.5001/omj.2018.72
   PubMedGoogle Scholar
• Book L, Hart A, Black J, Feolo M, Zone JJ, Neuhausen SL. Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. Am J Med Genet. 2001;98(1):70–74. doi:10.1002/1096-8628(20010101)98:1<70::AID-AJMG1002>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–76;quiz 677. doi:10.1038/ajg.2013.79
   Web of Science ®Google Scholar
• Uibo O, Teesalu K, Metskula K, et al. Screening for celiac disease in Down’s syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies. World J Gastroenterol. 2006;12(9):1430–1434. doi:10.3748/wjg.v12.i9.1430
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Iardino P, Resse M, et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol. 2004;38(10):901–905. doi:10.1097/00004836-200411000-00014
   PubMed Web of Science ®Google Scholar
• Martins EV, Gaburri AK. Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C. Arq Gastroenterol. 2004;41:132–133. doi:10.1590/S0004-28032004000200012
   PubMedGoogle Scholar
• Hernandez L, Johnson TC, Naiyer AJ, et al. Chronic hepatitis C virus and celiac disease, is there an association? Dig Dis Sci. 2008;53:256–261. doi:10.1007/s10620-007-9851-z
   PubMed Web of Science ®Google Scholar
• Ruggeri C, La Masa AT, Rudi S, et al. Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection. Dig Dis Sci. 2008;53(8):2151–2155. doi:10.1007/s10620-007-0146-1
   PubMed Web of Science ®Google Scholar
• Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia. 2006;49(6):1179–1182. doi:10.1007/s00125-006-0231-6
   PubMed Web of Science ®Google Scholar
• Pierce MJ, LaFranchi SH, Pinter JD. Characterization of thyroid abnormalities in a large cohort of children with Down syndrome. Horm Res Paediatr. 2017;87(3):170–178. doi:10.1159/000457952
   PubMed Web of Science ®Google Scholar
• Mortimer GL, Gillespie KM. Early onset of autoimmune diabetes in children with Down syndrome—two separate aetiologies or an immune system pre-programmed for autoimmunity? Curr Diab Rep. 2020;20(9). doi:10.1007/s11892-020-01318-8
   PubMed Web of Science ®Google Scholar
• Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabetic Med. 1998;15(2):160–163. doi:10.1002/(sici)1096-9136(199802)15:2<160::Aid-dia537>3.0.Co;2-j
   PubMed Web of Science ®Google Scholar
• Zornitzki T. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol. 2015;21(1):233. doi:10.3748/wjg.v21.i1.233
   PubMed Web of Science ®Google Scholar
• Gillespie KM, Dix RJ, Williams AJ, et al. Islet autoimmunity in children with Down’s syndrome. Diabetes. 2006;55(11):3185–3188. doi:10.2337/db06-0856
   PubMed Web of Science ®Google Scholar
• Aitken RJ, Mehers KL, Williams AJ, et al. Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care. 2013;36(5):1181–1185. doi:10.2337/dc12-1712
   PubMed Web of Science ®Google Scholar
• Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003;18(6):549–558. doi:10.1046/j.1365-2036.2003.01681.x
   PubMed Web of Science ®Google Scholar
• Molleston JP, Mellman W, Narkewicz MR, et al. Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2013;56(3):304–310. doi:10.1097/MPG.0b013e3182774cae
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Saitoh S. Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy. Diabetes Care. 2011;34(2):471–473. doi:10.2337/dc10-1237
   PubMed Web of Science ®Google Scholar
• Fort P, Lifshitz F, Bellisario R, et al. Abnormalities of thyroid function in infants with Down syndrome. J Pediatr. 1984;104(4):545–549. doi:10.1016/s0022-3476(84)80544-2
   PubMed Web of Science ®Google Scholar
• Selikowitz M. Health problems and health checks in school-aged children with Down syndrome. J Paediatr Child Health. 1992;28(5):383–386. doi:10.1111/j.1440-1754.1992.tb02697.x
   PubMed Web of Science ®Google Scholar
• Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Annerén G. Thyroid dysfunction in Down’s syndrome: relation to age and thyroid autoimmunity. Arch Dis Child. 1998;79(3):242–245. doi:10.1136/adc.79.3.242
   PubMed Web of Science ®Google Scholar
• Tüysüz B, Beker DB. Thyroid dysfunction in children with Down’s syndrome. Acta paediatrica. 2001;90(12):1389–1393. doi:10.1080/08035250152708770
   PubMed Web of Science ®Google Scholar
• Shott SR, Joseph A, Heithaus D. Hearing loss in children with Down syndrome. Int J Pediatr Otorhinolaryngol. 2001;61(3):199–205. doi:10.1016/s0165-5876(01)00572-9
   PubMed Web of Science ®Google Scholar
• Schepis C, Barone C, Siragusa M, Pettinato R, Romano C. An updated survey on skin conditions in Down syndrome. Dermatology. 2002;205(3):234–238. doi:10.1159/000065859
   PubMed Web of Science ®Google Scholar
• Chen MH, Chen SJ, Su LY, Yang W. Thyroid dysfunction in patients with Down syndrome. Acta paediatrica Taiwanica. 2007;48(4):191–195.
   PubMedGoogle Scholar
• Martínez E, Castañeda D, Jaramillo S, et al. Altered immune parameters correlate with infection-related hospitalizations in children with Down syndrome. Hum Immunol. 2016;77(7):594–599. doi:10.1016/j.humimm.2016.05.004
   PubMed Web of Science ®Google Scholar
• Noble SE, Leyland K, Findlay CA, et al. School based screening for hypothyroidism in Down’s syndrome by dried blood spot TSH measurement. Arch Dis Child. 2000;82(1):27–31. doi:10.1136/adc.82.1.27
   PubMed Web of Science ®Google Scholar
• van Trotsenburg AS, Vulsma T, van Rozenburg-marres SL, et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005;90(6):3304–3311. doi:10.1210/jc.2005-0130
   PubMed Web of Science ®Google Scholar
• Goday-Arno A, Cerda-Esteva M, Flores-le-roux JA, Chillaron-Jordan JJ, Corretger JM, Cano-Pérez JF. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol. 2009;71(1):110–114. doi:10.1111/j.1365-2265.2008.03419.x
   PubMed Web of Science ®Google Scholar
• Serranti D, Indolfi G, Nebbia G, et al. Transient hypothyroidism and autoimmune thyroiditis in children with chronic hepatitis C treated with pegylated-interferon-α-2b and ribavirin. Pediatr Infect Dis J. 2018;37(4):287–291. doi:10.1097/INF.0000000000001791
   PubMed Web of Science ®Google Scholar
• Hameed MA, Mehmood A, Farooq MA, Tayyab GUN, Haq Toor IU. Hypothyroidism in hepatitis C patients on pegylated interferon therapy. J Ayub Med Coll. 2016;28(4):706–708.
   PubMedGoogle Scholar
• Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol. 2009;24(6):1024–1029. doi:10.1111/j.1440-1746.2009.05812.x
   PubMed Web of Science ®Google Scholar
• Yan Z, Fan K, Fan Y, et al. Thyroid dysfunction in Chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors. Hepat Mon. 2012;12(9):e6390. doi:10.5812/hepatmon.6390
   PubMed Web of Science ®Google Scholar
• Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon α-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004;164(21):2371–2376. doi:10.1001/archinte.164.21.2371
   PubMedGoogle Scholar
• Földes I, Dávid K, Horváth G, Osztrogonácz H, Jankovics K, Tolvaj G. [Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha]. Orv Hetil. 2004;145(23):1211–1216. [Danish].
   PubMedGoogle Scholar
• Durelli L, Ferrero B, Oggero A, et al. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology. 2001;57(8):1363–1370. doi:10.1212/wnl.57.8.1363
   PubMed Web of Science ®Google Scholar
• Pavan MH, Pavin EJ, Gonçales FL, Zantut-Wittmann DE, Wittmann DE. Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C. Braz J Infect Dis. 2011;15(5):449–456. doi:10.1016/s1413-8670(11)70226-4
   PubMed Web of Science ®Google Scholar
• Kozielewicz D, Zalesna A, Dybowska D. Can pegylated interferon alpha 2a cause development of thyroid disorders in patients with chronic hepatitis B? Expert Opin Drug Saf. 2014;13(8):1009–1014. doi:10.1517/14740338.2014.921156
   PubMed Web of Science ®Google Scholar
• Al-Maweri SA, Tarakji B, Al-Sufyani GA, Al-Shamiri HM, Gazal G. Lip and oral lesions in children with Down syndrome. A controlled study. J Clin Exp Dent. 2015;7(2):e284–8. doi:10.4317/jced.52283
   PubMedGoogle Scholar
• Scully C, van Bruggen W, Diz Dios P, Casal B, Porter S, Davison M-F. Down syndrome: lip lesions (angular stomatitis and fissures) and Candida albicans. Br J Dermatol. 2002;147:37–40. doi:10.1046/j.1365-2133.2002.04741.x
   PubMed Web of Science ®Google Scholar
• Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol. 2007;24(3):317–320. doi:10.1111/j.1525-1470.2007.00412.x
   PubMed Web of Science ®Google Scholar
• Madan V, Williams J, Lear JT. Dermatological manifestations of Down’s syndrome. Clin Exp Dermatol. 2006;31(5):623–629. doi:10.1111/j.1365-2230.2006.02164.x
   PubMed Web of Science ®Google Scholar
• Giovanardi G, Chiricozzi A, Bianchi L, et al. Hidradenitis suppurativa associated with Down syndrome is characterized by early age at diagnosis. Dermatology. 2018;234(1–2):66–70. doi:10.1159/000487799
   PubMed Web of Science ®Google Scholar
• Carlstedt K, Krekmanova L, Dahllöf G, Ericsson B, Braathen G, Modéer T. Oral carriage of Candida species in children and adolescents with Down’s syndrome. Int J Paediatr Dent. 1996;6(2):95–100. doi:10.1111/j.1365-263x.1996.tb00219.x
   PubMedGoogle Scholar
• Mohiddin G, Narayanaswamy AB, Masthan KM, Nagarajan A, Panda A, Behura SS. Oral Candidal and Streptococcal carriage in Down syndrome patients. J Nat Sci Biol Med. 2015;6(2):300–305. doi:10.4103/0976-9668.159983
   PubMedGoogle Scholar
• Maranhão FC, Mendonça NM, Teixeira TC, et al. Molecular identification of Candida species in the oral microbiota of individuals with Down syndrome: a case-control study. Mycopathologia. 2020;185(3):537–543. doi:10.1007/s11046-020-00457-6
   PubMed Web of Science ®Google Scholar
• Megged O, Schlesinger Y. Down syndrome and streptococcus group A disease in hospitalized children. Acta paediatrica. 2010;99(6):796–797. doi:10.1111/j.1651-2227.2009.01640.x
   PubMed Web of Science ®Google Scholar
• Sánchez-Luna M, Medrano C, Lirio J. Down syndrome as risk factor for respiratory syncytial virus hospitalization: a prospective multicenter epidemiological study. Influenza Other Respi Viruses. 2017;11(2):157–164. doi:10.1111/irv.12431
   PubMed Web of Science ®Google Scholar
• Yancey CL, Zmijewski C, Athreya BH, Doughty RA. Arthropathy of Down’s syndrome. Arthritis Rheum. 1984;27(8):929–934. doi:10.1002/art.1780270813
   PubMed Web of Science ®Google Scholar
• Foley CM, Deely DA, MacDermott EJ, Killeen OG. Arthropathy of Down syndrome: an under-diagnosed inflammatory joint disease that warrants a name change. RMD Open. 2019;5(1):e000890. doi:10.1136/rmdopen-2018-000890
   PubMed Web of Science ®Google Scholar
• Passos de Souza E, Evangelista Segundo PT, Jose FF, Lemaire D, Santiago M. Rheumatoid arthritis induced by α-interferon therapy. Clin Rheumatol. 2001;20(4):297–299. doi:10.1007/pl00011206
   PubMed Web of Science ®Google Scholar
• Verweyen EL, Schulert GS. Interfering with Interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology. 2021. doi:10.1093/rheumatology/keab673
   PubMed Web of Science ®Google Scholar
• Hartley D, Blumenthal T, Carrillo M, et al. Down syndrome and Alzheimer’s disease: common pathways, common goals. Alzheimers Dement. 2015;11(6):700–709. doi:10.1016/j.jalz.2014.10.007
   PubMed Web of Science ®Google Scholar
• Cohen AD, Head E, Lee JH. Alzheimer’s disease in aging Down syndrome. Dev Neurobiol. 2019;79(7):611–612. doi:10.1002/dneu.22717
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kiyota T, Horiba M, et al. Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170(2):680–692. doi:10.2353/ajpath.2007.060378
   PubMed Web of Science ®Google Scholar
• Taylor JM, Moore Z, Minter MR, Crack PJ. Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer’s disease. J Neural Transm. 2018;125(5):797–807. doi:10.1007/s00702-017-1745-4
   PubMed Web of Science ®Google Scholar
• Moore Z, Mobilio F, Walker FR, Taylor JM, Crack PJ. Abrogation of type-I interferon signalling alters the microglial response to Aβ1–42. Sci Rep. 2020;10(1):3153. doi:10.1038/s41598-020-59917-0
   PubMed Web of Science ®Google Scholar
• Roy ER, Wang B, Wan YW, et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest. 2020;130(4):1912–1930. doi:10.1172/JCI133737
   PubMed Web of Science ®Google Scholar
• Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012;36(4):503–514. doi:10.1016/j.immuni.2012.03.013
   PubMed Web of Science ®Google Scholar
• Kong XF, Vogt G, Itan Y, et al. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Hum Mol Genet. 2013;22(4):769–781. doi:10.1093/hmg/dds484
   PubMed Web of Science ®Google Scholar
• Hemann EA, Gale M, Savan R. Interferon lambda genetics and biology in regulation of viral control. Front Immunol. 2017;8:1707. doi:10.3389/fimmu.2017.01707
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Mohamad SM, Young DF, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. 2015;7(307):307ra154. doi:10.1126/scitranslmed.aac4227
   PubMed Web of Science ®Google Scholar
• Hernandez N, Bucciol G, Moens L, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216(9):2057–2070. doi:10.1084/jem.20182295
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi:10.1126/science.abd4570
   PubMed Web of Science ®Google Scholar
• Bastard P, Manry J, Chen J, et al. Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency. J Clin Invest. 2021;131(1). doi:10.1172/JCI139980
   Web of Science ®Google Scholar
• Vogt G, Bustamante J, Chapgier A, et al. Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. J Exp Med. 2008;205(8):1729–1737. doi:10.1084/jem.20071987
   PubMed Web of Science ®Google Scholar
• Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26(6):454–470. doi:10.1016/j.smim.2014.09.008
   PubMed Web of Science ®Google Scholar
• Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–2045. doi:10.1056/NEJMoa0907206
   PubMed Web of Science ®Google Scholar
• Pelleri MC, Cattani C, Vitale L, et al. Integrated quantitative transcriptome maps of human trisomy 21 tissues and cells. Front Genet. 2018;9:125. doi:10.3389/fgene.2018.00125
   PubMed Web of Science ®Google Scholar
• Prandini P, Deutsch S, Lyle R, et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am J Hum Genet. 2007;81:252–263. doi:10.1086/519248
   PubMed Web of Science ®Google Scholar
• Takaoka A, Mitani Y, Suemori H, et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science. 2000;288(5475):2357–2360. doi:10.1126/science.288.5475.2357
   PubMed Web of Science ®Google Scholar
• Meuwissen MEC, Schot R, Buta S, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med. 2016;213(7):1163–1174. doi:10.1084/jem.20151529
   PubMed Web of Science ®Google Scholar
• Zhang X, Bogunovic D, Payelle-Brogard B, et al. Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature. 2015;517(7532):89–93. doi:10.1038/nature13801
   PubMed Web of Science ®Google Scholar
• Blouin CM, Hamon Y, Gonnord P, et al. Glycosylation-dependent IFN-γR partitioning in lipid and actin nanodomains is critical for JAK activation. Cell. 2016;166(4):920–934. doi:10.1016/j.cell.2016.07.003
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723. doi:10.1084/jem.20021553
   PubMed Web of Science ®Google Scholar
• Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding human autoimmunity and autoinflammation through transcriptomics. Annu Rev Immunol. 2017;35:337–370. doi:10.1146/annurev-immunol-051116-052225
   PubMed Web of Science ®Google Scholar
• Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238(1):91–98. doi:10.1111/j.1749-6632.2011.06220.x
   PubMedGoogle Scholar
• Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213(12):2527–2538. doi:10.1084/jem.20161596
   PubMed Web of Science ®Google Scholar
• Rice GI, Forte GMA, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12(12):1159–1169. doi:10.1016/S1474-4422(13)70258-8
   PubMed Web of Science ®Google Scholar
• Liu L, Okada S, Kong X-F, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635–1648. doi:10.1084/jem.20110958
   PubMed Web of Science ®Google Scholar
• Ugazio AG, Maccario R, Notarangelo LD, Burgio GR. Immunology of Down syndrome: a review. Am J Med Genet Suppl. 1990;7:204–212. doi:10.1002/ajmg.1320370742
   PubMedGoogle Scholar
• Malle L, Bogunovic D. Down syndrome and type I interferon: not so simple. Curr Opin Immunol. 2021;72:196–205. doi:10.1016/j.coi.2021.06.006
   PubMed Web of Science ®Google Scholar
• Verstegen RHJ, Kusters MAA. Inborn errors of adaptive immunity in Down syndrome. J Clin Immunol. 2020;40(6):791–806. doi:10.1007/s10875-020-00805-7
   PubMed Web of Science ®Google Scholar
• Fischer A. Recent advances in understanding the pathophysiology of primary T cell immunodeficiencies. Trends Mol Med. 2015;21:408–416. doi:10.1016/j.molmed.2015.04.002
   PubMed Web of Science ®Google Scholar
• Gil MP, Ploquin MJY, Watford WT, et al. Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood. 2012;120(18):3718–3728. doi:10.1182/blood-2012-05-428672
   PubMed Web of Science ®Google Scholar
• Tangye SG. Genetic susceptibility to EBV infection: insights from inborn errors of immunity. Hum Genet. 2020;139(6–7):885–901. doi:10.1007/s00439-020-02145-3
   PubMed Web of Science ®Google Scholar
• Gruber CN, Calis JJA, Buta S, et al. Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function. Immunity. 2020;53(3):672–684.e11. doi:10.1016/j.immuni.2020.07.006
   PubMed Web of Science ®Google Scholar
• Del Bel KL, Ragotte RJ, Saferali A, et al. JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. J Allergy Clin Immunol. 2017;139(6):2016–2020e5. doi:10.1016/j.jaci.2016.12.957
   PubMed Web of Science ®Google Scholar
• Gruber C, Martin-Fernandez M, Ailal F, et al. Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy. J Exp Med. 2020;217(5). doi:10.1084/jem.20192319
   PubMed Web of Science ®Google Scholar
• Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood: Am Soc Hematol. 2015;125(4):591–599. doi:10.1182/blood-2014-09-602763
   Google Scholar
• Casanova JL. Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci U S A. 2015;112(51):E7118–27. doi:10.1073/pnas.1521644112
   PubMed Web of Science ®Google Scholar
• Malle L, Bastard P, Martin-Nalda A, et al. Atypical inflammatory syndrome triggered by SARS-CoV-2 in infants with Down syndrome. J Clin Immunol. 2021;41(7):1457–1462. doi:10.1007/s10875-021-01078-4
   PubMed Web of Science ®Google Scholar
• Maroun LE, Heffernan TN, Hallam DM. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. J Interferon Cytokine Res. 2000;20(2):197–203. doi:10.1089/107999000312612
   PubMed Web of Science ®Google Scholar
• Tuttle KD, Waugh KA, Araya P, et al. JAK1 inhibition blocks lethal immune hypersensitivity in a mouse model of Down syndrome. Cell Rep. 2020;33(7):108407. doi:10.1016/j.celrep.2020.108407
   PubMed Web of Science ®Google Scholar
• Powers RK, Culp-Hill R, Ludwig MP, et al. Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nat Commun. 2019;10(1):4766. doi:10.1038/s41467-019-12739-9
   PubMedGoogle Scholar
• Charbit-Henrion F, Begue B, Sierra A, et al. Copy number variations and founder effect underlying complete IL-10Rβ deficiency in Portuguese kindreds. PLoS One. 2018;13(10):e0205826. doi:10.1371/journal.pone.0205826
   PubMed Web of Science ®Google Scholar
• Pulendran B, Davis MM. The science and medicine of human immunology. Science. 2020;369(6511):eaay4014. doi:10.1126/science.aay4014
   PubMed Web of Science ®Google Scholar
• da Rosa Utiyama SR, Nisihara RM, Nass FR, Oliveira NP, Fiedler PT, de Messias-reason IT. Autoantibodies in patients with Down syndrome: early senescence of the immune system or precocious markers for immunological diseases? J Paediatr Child Health. 2008;44(4):182–186. doi:10.1111/j.1440-1754.2007.01229.x
   PubMed Web of Science ®Google Scholar
• Malakhova OA, Kim KI, Luo JK, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006;25(11):2358–2367. doi:10.1038/sj.emboj.7601149
   PubMed Web of Science ®Google Scholar
• Jimenez Fernandez D, Hess S, Knobeloch KP. Strategies to target ISG15 and USP18 toward therapeutic applications. Front Chem. 2019;7:923. doi:10.3389/fchem.2019.00923
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol. 2011;11(4):239–250. doi:10.1038/nri2958
   PubMed Web of Science ®Google Scholar
• Gough DJ, Messina NL, Clarke CJ, et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 2012;36:166–174. doi:10.1016/j.immuni.2012.01.011
   PubMed Web of Science ®Google Scholar
• Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down’s syndrome. Nature. 2008;451(7174):73–75. doi:10.1038/nature06446
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Tofacitinib for immune skin conditions in Down Syndrome. Available from: https://clinicaltrials.gov/ct2/show/NCT04246372. Accessed September 30, 2021.
   Google Scholar
• Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep. 2019;5(4):365–367. doi:10.1016/j.jdcr.2019.02.007
   PubMedGoogle Scholar
• Pham AT, Rachubinski AL, Enriquez-Estrada B, Worek K, Griffith M, Espinosa JM. JAK inhibition for treatment of psoriatic arthritis in Down syndrome. Rheumatology. 2021;60(9):e309–e311. doi:10.1093/rheumatology/keab203
   PubMed Web of Science ®Google Scholar
• Yu YE, Xing Z, Do C, et al. Genetic and epigenetic pathways in Down syndrome: insights to the brain and immune system from humans and mouse models. Prog Brain Res. 2020;251:1–28. doi:10.1016/bs.pbr.2019.09.002
   PubMed Web of Science ®Google Scholar
• Du Y, Shan LF, Cao ZZ, Feng JC, Cheng Y. Prevalence of celiac disease in patients with Down syndrome: a meta-analysis. Oncotarget. 2018;9:5387–5396. doi:10.18632/oncotarget.23624
   PubMedGoogle Scholar
• Agardh D, Nilsson A, Carlsson A, Kockum I, Lernmark A, Ivarsson SA. Tissue transglutaminase autoantibodies and human leucocyte antigen in Down’s syndrome patients with coeliac disease. Acta paediatrica. 2002;91(1):34–38. doi:10.1080/080352502753457914
   PubMed Web of Science ®Google Scholar
• Alanay Y, Boduroğlu K, Tunçbilek E. Celiac disease screening in 100 Turkish children with Down syndrome. Turk J Pediatr. 2005;47(2):138–140.
   PubMed Web of Science ®Google Scholar
• Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823–836.e2. doi:10.1016/j.cgh.2017.06.037
   PubMed Web of Science ®Google Scholar
• Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923–931. doi:10.1210/jc.2013-2409
   PubMed Web of Science ®Google Scholar
• Bullard KM, Cowie CC, Lessem SE, et al. Prevalence of diagnosed diabetes in adults by diabetes type - United States, 2016. Morb Mortal Wkly Rep. 2018;67(12):359–361. doi:10.15585/mmwr.mm6712a2
   PubMed Web of Science ®Google Scholar